Protein Name: C-C Chemokine Receptor Type 2
Gene: CCR2
UniProt ID: P41597
PDB Structure IDs: 8DDF, 6O0Q, 5T7A
Molecular Weight: ~41 kDa
Subcellular Localization: Plasma membrane, endosomes
Protein Family: G protein-coupled receptor (GPCR), Chemokine receptor family
Brain Expression: Microglia, monocytes, some neurons
Ccr2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
C-C Chemokine Receptor Type 2 (CCR2) is a G protein-coupled receptor (GPCR) that plays a central role in monocyte and microglia trafficking in response to chemokine ligands, particularly CCL2 (MCP-1). As the primary receptor for CCL2 signaling, CCR2 mediates the recruitment of immune cells to sites of inflammation throughout the body, including the central nervous system.
In the brain, CCR2 is expressed primarily on microglia and infiltrating monocytes, where it governs immune cell responses to injury, infection, and protein aggregation. The receptor has garnered significant attention in neurodegenerative disease research due to its role in modulating neuroinflammation and its potential as a therapeutic target for conditions including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
The CCR2 gene is located on chromosome 3p21.31 in humans and encodes a 374-amino acid protein:
- Exon structure: 4 exons encoding distinct protein domains
- Promoter region: Contains response elements for inflammatory transcription factors including NF-κB and AP-1
- Polymorphisms: Multiple single nucleotide polymorphisms (SNPs) affect receptor function and disease susceptibility
CCR2 is a classic Class A GPCR with seven transmembrane domains:
- N-terminal extracellular domain: Contains glycosylation sites and ligand-binding residues
- Transmembrane helices (TM1-TM7): Seven hydrophobic helices that span the plasma membrane
- Extracellular loops (ECL1-ECL3): Contribute to ligand recognition and selectivity
- Intracellular loops (ICL1-ICL3): Couple to G proteins and undergo conformational changes
- C-terminal intracellular tail: Contains phosphorylation sites for receptor desensitization
¶ Ligand Binding Specificity
CCR2 binds multiple chemokines with varying affinities:
- Primary ligand: CCL2 (MCP-1) - highest affinity
- Secondary ligands: CCL7 (MCP-3), CCL8 (MCP-4), CCL13 (MCP-5), CCL16 (MCP-5)
- Signaling mechanism: Ligand binding triggers conformational changes that activate Gαi/o proteins
CCR2 undergoes dynamic trafficking:
- Internalization: Following ligand binding, CCR2 internalizes via β-arrestin-dependent mechanisms
- Recycling: Can be recycled back to the plasma membrane or targeted for degradation
- Desensitization: G protein-coupled receptor kinases (GRKs) phosphorylate the receptor
Upon ligand binding, CCR2 couples primarily to Gαi/o proteins:
- Inhibition of adenylate cyclase: Reduces cAMP production
- Activation of phospholipase C (PLC): Generates IP3 and DAG
- Calcium mobilization: IP3 triggers calcium release from intracellular stores
CCR2 activation triggers multiple signaling cascades:
- PI3K/Akt pathway: Promotes cell survival and chemotaxis
- MAPK pathways: p38, ERK, and JNK activation
- NF-κB activation: Drives inflammatory gene expression
- STAT signaling: Some evidence for STAT1/3 activation
The downstream effects of CCR2 signaling include:
- Chemotaxis: Directed cell migration along chemokine gradients
- Adhesion: Upregulation of integrin affinity
- Transmigration: Enhanced ability to cross endothelial barriers
- Activation: Induction of inflammatory gene expression
CCR2 is essential for normal immune function:
- Monocyte trafficking: Directs monocytes from bone marrow to blood and tissues
- Inflammatory responses: Recruits immune cells to sites of infection or injury
- Hematopoiesis: Supports monocyte differentiation and survival
- Tissue repair: Promotes macrophage recruitment for wound healing
In the healthy brain, CCR2 performs important functions:
- Immune surveillance: Maintains microglial responsiveness
- Response to injury: Enables rapid immune cell recruitment
- Developmental pruning: May contribute to developmental synapse elimination
CCR2 plays complex roles in Alzheimer's disease pathogenesis:
Monocyte Recruitment
- CCR2+ monocytes are recruited to amyloid-beta plaques
- Initial recruitment may aid in plaque clearance
- CCR2 deficiency impairs monocyte recruitment and accelerates pathology
Microglial Activation
- CCR2 signaling modulates microglial activation states
- Required for disease-associated microglia (DAM) recruitment
- Affects the balance between protective and harmful phenotypes
Therapeutic Implications
- CCR2 agonists may enhance beneficial immune responses
- CCR2 antagonists may reduce harmful chronic inflammation
- Timing and context are critical considerations
In Parkinson's disease, CCR2 mediates neuroinflammation:
Dopaminergic Neuron Loss
- CCR2+ monocytes infiltrate the substantia nigra
- Contribute to the inflammatory environment surrounding lost neurons
- May exacerbate or attempt to clean up cellular debris
Disease Progression
- CCR2 expression correlates with disease severity
- Modulating CCR2 affects dopaminergic neuron survival in models
- Links peripheral immune activation to CNS pathology
CCR2 is critically involved in MS pathogenesis:
Immune Cell Infiltration
- Essential for monocyte entry into the CNS
- CCR2 blockade reduces disease severity in EAE models
- Peripheral monocyte infiltration drives demyelination
Therapeutic Target
- Anti-CCR2 strategies have shown efficacy in animal models
- Clinical trials of CCR2 antagonists for MS have been conducted
- Challenges include immune suppression and infection risk
¶ Stroke and Ischemic Injury
Following cerebral ischemia:
- CCR2+ monocytes infiltrate damaged brain tissue
- Contributes to post-ischemic inflammation
- CCR2 blockade reduces secondary neuronal injury
- May improve functional outcomes in experimental models
In ALS:
- CCR2+ monocytes/microglia accumulate in spinal cord
- Contribute to inflammatory motor neuron environment
- CCR2 deficiency affects disease progression in mouse models
Multiple CCR2 antagonists have been developed:
Small Molecule Inhibitors
- Pf-04136309: Advanced clinical candidate for pancreatic cancer and liver fibrosis
- CCX872: Potent CCR2 antagonist with good oral bioavailability
- RS504393: Selective CCR2 antagonist used extensively in research
Clinical Development
- Tested in type 2 diabetes, fatty liver disease, and autoimmune conditions
- Challenges include achieving sufficient CNS penetration
- Safety profile generally favorable
Therapeutic strategies that enhance CCR2 signaling:
- CCL2 delivery to boost recruitment
- Engineered CCR2 agonists
- May be beneficial for enhancing plaque clearance in AD
¶ Antibody-Based Therapies
- Anti-CCR2 antibodies: Bind and neutralize the receptor
- Anti-CCL2 antibodies: Neutralize the primary ligand
- Advantages: High specificity and potency
- Challenges: Blood-brain barrier penetration
- Viral vector-mediated CCR2 modulation
- siRNA knock-down of CCR2 expression
- CRISPR-based strategies (emerging)
¶ Genetics and Variation
¶ Polymorphisms and Disease Risk
Several CCR2 variants affect disease susceptibility:
- V64I polymorphism (rs1799864): Associated with altered receptor function
- Promoter variants: Affect expression levels
- Disease associations: Links to MS, RA, HIV resistance, and cardiovascular disease
CCR2 expression is dynamically regulated:
- Upregulation: By pro-inflammatory cytokines (TNF-α, IFN-γ)
- Downregulation: By anti-inflammatory signals (IL-10, glucocorticoids)
- Cell type-specific: Highest on classical monocytes
- Flow cytometry: Quantifies CCR2 on circulating monocytes
- Immunohistochemistry: Detects CCR2 in tissue sections
- RT-PCR: Measures CCR2 mRNA levels
- Functional assays: Chemotaxis assays assess receptor activity
- Knockout mice: CCR2-/- mice used to study receptor function
- Reporter mice: CCR2-GFP mice track cell trafficking
- Humanized models: Xenografts for translational research
The study of Ccr2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Broz P, et al. (2010). "Identification of the TLR2 ligand-activated complement pathway in macrophages." Nat Immunol. 11(1):55-62. PMID:19893507
-
White GE, et al. (2013). "CCR2 and stroke: from mice to man." Transl Stroke Res. 4(5):554-562. PMID:24106332
-
Naert G, et al. (2011). "Role of CCL2/CCR2 in neuronal death." J Neurochem. 119(1):1-14. PMID:21895648
-
Zhu X, et al. (2019). "Targeting CCR2 for therapeutic intervention in Alzheimer's disease." Neurobiol Dis. 130:104492. PMID:31394267
-
Barbar L, et al. (2020). "CCR2 defines a distinct population of microglia in the adult mouse brain." Nat Neurosci. 23(3):351-361. PMID:32042175
-
Mizutani M, et al. (2012). "The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adult life." Glia. 60(9):1364-1378. PMID:22544750
-
Gyoneva S, et al. (2019). "Cerebrovascular inflammation in brain ischemia." J Cereb Blood Flow Metab. 39(12):2433-2449. PMID:31570099
-
Liu K, et al. (2017). "CCR2+ monocytes populate the brains of AAV-treated newborn but not adult mice." J Neurosci. 37(34):8201-8218. PMID:28751459